SP 600125

Drug Profile

SP 600125

Alternative Names: SP600125

Latest Information Update: 19 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Signal Research Division
  • Class Antirheumatics
  • Mechanism of Action JNK mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase 8 inhibitors; Mitogen-activated protein kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allotransplant rejection; Asthma; Cancer; Cerebral ischaemia; Rheumatoid arthritis

Most Recent Events

  • 05 Feb 2008 No development reported - Preclinical for Allotransplant rejection in USA (unspecified route)
  • 05 Feb 2008 No development reported - Preclinical for Cerebral ischaemia in China (unspecified route)
  • 20 Oct 2005 Preclinical trials in Cerebral ischaemia in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top